The risk of malignancies in patients receiving hematopoietic stem cell transplantation: a systematic review and meta-analysis

@article{Heydari2020TheRO,
  title={The risk of malignancies in patients receiving hematopoietic stem cell transplantation: a systematic review and meta-analysis},
  author={Keyvan Heydari and Amir Shamshirian and P. Lotfi-Foroushani and Amir Reza Aref and Akbar Hedayatizadeh-Omran and Michael Ahmadi and G. Janbabei and Shahrbanou Keyhanian and Ehsan Zaboli and Seyyes Mostafa Ghasemzadeh and Reza Alizadeh-Navaei},
  journal={Clinical and Translational Oncology},
  year={2020},
  pages={1-13}
}
Introduction Hematopoietic stem cell transplantation (HSCT) is widely used in the treatment of malignant and non-malignant diseases. Due to advances in the number of survivors of this treatment, the number of survivors is increasing, but the late complications of this therapeutic approach such as secondary cancers have been long term and have not been fully controlled. Methods The present meta-analysis study was performed by considering English-language articles in the databases including Web… 
Reply to: “The risk of malignancies in patients receiving hematopoietic stem cell transplantation: a systematic review and meta-analysis”
TLDR
The meta-analysis findings showed that the risk of secondary cancers after HSCT was significantly increased in most types of cancers, and diagnostic tests for common cancers should be included in the screening program of patients for the prevention and early detection of high-risk cancers.
Letter to Editor regarding “The risk of malignancies in patients receiving hematopoietic stem cell transplantation: a systematic review and meta‑analysis”
TLDR
The authors concluded that receiving hematopoietic stem cells was significantly associated with an increase in most types of cancer, and utilized the “PRISMA flow diagram” without using it in the method and stating anything more about it.
Long-term safety of photobiomodulation therapy for oral mucositis in hematopoietic cell transplantation patients: a 15-year retrospective study
TLDR
Hospital Israelita Albert Einstein, University of Florida College of Dentistry, New York, USA.
Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches
TLDR
An approach to arresting cell division with mitomycin C in endothelial and smooth muscle cells from cardiac explant, which prevents the risk of malignancy from dividing cells in vascular surgery is pioneered and believed to bring closer the development of safe cell products for regenerative medicine.
Facilitators and obstacles to couples' intimacy after hematopoietic stem cell transplantation: a qualitative study.
TLDR
Couples’ intervention delivered in cancer care should be adapted by focusing on specific factors that maintain or enhance couples’ intimacy, as highlighted in this study.
Label-free on chip quality assessment of cellular blood products using real-time deformability cytometry.
TLDR
The results demonstrate that label-free mechano-phenotyping can be used as a potential biomarker for quality assessment of cell-based pharmaceutical products and the engraftment time of patients' platelets and leukocytes after transplantation of HPSC products.

References

SHOWING 1-10 OF 40 REFERENCES
Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study.
  • A. Cohen, A. Rovelli, G. Socié
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Long-term survivors of HSCT are at risk for STCs, and results should promote efforts in screening for early detection and treatment guidelines of secondary thyroid cancer after HSCT, especially in patients who receive transplants during childhood and adolescence.
Solid cancers after allogeneic hematopoietic cell transplantation.
TLDR
Allogeneic transplant survivors, particularly those irradiated at young ages, face increased risks of solid cancers, supporting strategies to promote lifelong surveillance among these patients.
Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.
  • Y. Atsuta, R. Suzuki, Y. Kodera
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2014
TLDR
Recipients of allogeneic HSCT had a significantly higher ∼2-fold risk of developing secondary solid cancers than the general population, and Lifelong screening for high-risk organ sites, especially oral or esophageal cancers, is important for recipients with active, or a history of, chronic GVHD.
Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis
TLDR
The data suggest that early detection of secondary cancers is very important in prolonging overall survival and that extensive chronic GVHD and age over 45 years at the time of transplantation were associated with a higher risk for solid cancers.
New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors.
TLDR
The data reveal that the risk of PTMs, especially solid tumors, continues to increase even 20 years after transplant, necessitating long-term close follow-up for these patients.
Solid cancers after bone marrow transplantation.
  • S. Bhatia, A. D. Louie, S. Forman
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
The risk of radiation-associated solid tumor development after BMT is likely to increase with longer follow-up, and underscores the importance of close monitoring of patients who undergo BMT.
Secondary solid tumors after allogeneic hematopoietic SCT in Japan
TLDR
The data suggest that the incidence and risk factors of secondary solid tumors in Japanese allo-HSCT recipients are comparable to those reported in Western countries and emphasize that the early detection of solid tumors has a crucial role in improving OS.
Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.
  • O. Ringdén, R. Brazauskas, N. Majhail
  • Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2014
Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party.
TLDR
It is concluded that female survivors of allogeneic HCT are at increased risk of breast cancer and should be educated about the need for regular screening.
Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced
TLDR
The risk of secondary malignancies is not reduced and is even possibly increased in the era of fludarabine-based RIC/RTC, and patients and physicians should be aware of this association and life-long cancer screening is required for all transplant survivors.
...
...